ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Adjuvant chemotherapy trials for non-small cell lung cancer

Adjuvant chemotherapy trials for non-small cell lung cancer
Study Stage Chemo RT Number of patients 5 year survival
Chemo Observe P-value
ALPI*[1] I, II, IIIA MVdP ± 1088 +1 percent --- 0.59
IALT*[2] I, II, III PE, PN, PV ± 1867 44 percent 40 percent 0.03
BLT*[3] I, II, III MVP, MIP, PN, PVd ± 381 58 percent 60 percent 0.90
JBR.10*[4] IB, II PN – 482 69 percent 54 percent 0.002
ANITA*[5] I, II, IIIA  PN  +/– 840  +8.6 percent  ---  0.017 
CALGB[6] IB CT – 344 60 percent 58 percent 0.125
P: cisplatin; E: etoposide; N: vinorelbine; V: vinblastine; M: mitomycin; I: ifosfamide; C: carboplatin; Vd: vindesine; RT: radiation therapy.
* Included in LACE meta-analysis [7].
¶ 2 year survival.
References:
  1. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453.
  2. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 2010; 28:35.
  3. Waller D, Gower N, Milroy MD, et al. The Big Lung Trial: determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the surgical setting (abstract). Proc Am Soc Clin Oncol 2003; 22:639.
  4. Butts CA, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010; 28:29.
  5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719.
  6. Strauss GM, Herndon JE 2nd, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043.
  7. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26:3552.
Graphic 90104 Version 5.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟